Table 3.

MAb-mediated neutralization of CCHFV strains in SW-13 cells.

Strain	8A1			11E7			30F7
Strain	PRNT₅₀ (μg/mL)	95% Confidence interval	Maximal inhibition (%)	PRNT₅₀ (μg/mL)	95% Confidence interval	Maximal inhibition (%)	PRNT₅₀ (μg/mL)	95% Confidence interval	Maximal inhibition (%)

IbAr10200	0.180	0.159–0.203	98.565 ± 0.359	0.332	0.242–0.454	68.062 ± 1.435	0.310	0.253–0.380	96.411 ± 0.949
Turkey	0.186	0.167–0.206	98.848 ± 0.230	0.284	0.235–0.344	86.636 ± 1.004	0.384	0.337–0.436	93.548 ± 0.610
Oman	0.165	0.135–0.202	98.463 ± 0.307	0.367	0.260–0.518	75.102 ± 1.844	0.230	0.191–0.276	84.016 ± 1.108
813040 UAE	0.570	0.486–0.668	95.101 ± 1.256	0.607	0.500–0.736	81.268 ± 1.525	3.931	1.003–15.400	78.0978 ± 1.605
813042 UAE	0.598	0.395–0.906	94.052 ± 0.372	0.593	0.404–0.871	69.888 ± 1.115	0.311	0.231–0.421	71.163 ± 4.581

MAbs 8A1, 11E7, and 30F7 were used in 2-fold dilution series from 10¹ to 1.6 × 10⁻¹ αg/mL in a plaque reduction/neutralization 50% (PRNT⁵⁰) assay with CCHFV strains IbAr10200, Turkey-812955, Oman-812956, 813040 UAE, and 813042 UAE. Plaques were counted visually, and percent inhibition was calculated by comparing the number of plaques formed by antibody-incubated CCHFV to those formed by mock-treated CCHFV. PRNT₅₀ values, 95% confidence intervals, and maximal inhibition for each antibody are shown. Maximal inhibition is shown as standard error about a mean (n = 3).